Promising Effect of Crizotinib on Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer in an Elderly Patient with a Poor Performance Status: A Case Report and Literature Review

被引：6
|
作者：
Matsuo, Norikazu [1 ]
Sekine, Akimasa [1 ]
Kato, Terufumi [1 ]
Hosoda, Chiaki [1 ]
Ito, Hiroyuki [1 ]
Baba, Tomohisa [1 ]
Umeda, Shigeaki [2 ]
Iwasawa, Tae [3 ]
Okudela, Koji [2 ]
Ogura, Takashi [1 ]
机构：
[1] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Kanagawa, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Pathol, Yokohama, Kanagawa, Japan
[3] Kanagawa Cardiovasc & Resp Ctr, Dept Radiol, Kanagawa, Japan
来源：
INTERNAL MEDICINE | 2016年 / 55卷 / 05期
关键词：
non-small cell lung cancer; anaplastic lymphoma kinase; crizotinib; performance status; elderly patients; CHEMOTHERAPY; SAFETY;
D O I：
10.2169/internalmedicine.55.5076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Crizotinib is highly effective for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether crizotinib has a beneficial effect on elderly patients with ALK-positive NSCLC with a poor performance status (PS). We herein present the case of an 85-year-old man with stage IV ALK-positive NSCLC, whose PS score was 4 due to pericardial and pleural effusions. After initiating crizotinib therapy, a drastic response was observed and the PS score improved to 0. Adverse effects were manageable. Our results indicate that crizotinib could be an important choice when treating elderly patients with ALK-positive NSCLC with poor PS.
引用
收藏
页码：507 / 509
页数：3
相关论文
共 50 条
  • [1] Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
    Osugi, Jun
    Owada, Yuki
    Yamaura, Takumi
    Muto, Satoshi
    Okabe, Naoyuki
    Matsumura, Yuki
    Higuchi, Mitsunori
    Suzuki, Hiroyuki
    Gotoh, Mitsukazu
    [J]. CASE REPORTS IN ONCOLOGY, 2016, 9 (01): : 51 - 55
  • [2] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Barrows, S. M.
    Wright, K.
    Copley-Merriman, C.
    Kaye, J. A.
    Chioda, M. D.
    Wiltshire, R.
    Torgersen, K. M.
    Masters, E. T.
    [J]. VALUE IN HEALTH, 2018, 21 : S49 - S50
  • [4] Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
    Frampton, James E.
    [J]. DRUGS, 2013, 73 (18) : 2031 - 2051
  • [5] Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
    James E. Frampton
    [J]. Drugs, 2013, 73 : 2031 - 2051
  • [6] VISUAL DISTURBANCES IN PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) TREATED WITH CRIZOTINIB
    Besse, B.
    Salgia, R.
    Solomon, B.
    Shaw, A.
    Kim, D.
    Schachar, R.
    Wilner, K.
    Reisman, A.
    Bartlett, C. H.
    Iyer, S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 416 - 416
  • [7] Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
    Salgia, Ravi
    Solomon, Benjamin J.
    Shaw, Alice Tsang
    Camidge, D. Ross
    Evans, Tracey L.
    Kim, Dong-Wan
    Shi, Yuankai
    Han, Ji-Youn
    De Pas, Tommaso Martino
    Ou, Sai-Hong Ignatius
    Bartlett, Cynthia Huang
    Wilner, Keith D.
    Reisman, Arlene
    Iyer, Shrividya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report
    Tian, Yu
    Huang, Jia
    Li, Chongwu
    Jiang, Long
    Lin, Hao
    Lu, Peiji
    Luo, Qingquan
    Yang, Guocai
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (12)
  • [9] ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
    Lin, H.
    Pan, X.
    Huang, H.
    Salvatore, G.
    Clarke, S.
    West, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S617 - S617
  • [10] Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer
    Imase, R.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Shimada, H.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1953 - S1953
12345